Resource data sheet
Prev.
Please review the QC test results indicated by check icon below as well as clone information before placing your order.

pENTER-EGFR T790M/L858R

Gateway(R) entry vector of human epidermal growth factor receptor (EGFR), EGFR-tyrosine kinase inhibitor (TKI) resistant and activating mutations.

Catalog number RDB15494
Resource name pENTER-EGFR T790M/L858R
Clone info. Gateway(R) entry vector of human epidermal growth factor receptor (EGFR) mutant, T790M and L858R, EGFR-tyrosine kinase inhibitor (TKI) resistant and activating mutations.
Comment cDNA was obtained from A549 cells. Expression was confirmed by the depositor with western blotting after cloned into pLenti6.3 vector (by LR clonase II reaction). This clone contains a cDNA fragment corresponding to the 258nt to 3890nt of NM_005228.4. Known differences (at least) : C to T substitution at 731nt (N, synonym) ; C to T substitution at 2626nt (T790M) ; T to G substitution at 2830nt (L858R).
Vector backbone pENTR (plasmid)
Size of vector backbone 2.6 kb
Selectable markers Kan^r
Gene/insert name human EGFR cDNA
Depositor|Developer Katayama, Ryohei |
Other clones in our bank

External Database
human EGFR

          Reference sequence
            
           

          Distribution information

          Please check terms and conditions set forth by the depositor, which are specified in the RIKEN BRC Catalog and/or Web Catalog.
          Terms and conditions for distribution In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of literature designated by the DEPOSITOR is requested. (Uchibori, K et al. Nat. Commun. 8: 14768, 2017)
          Ordering Please visit Information of Request for Distribution.[link] 
          Order form 
          [Credit Card Payment]  [Bank Transfer Payment]
          Material Transfer Agreement (MTA for use for not-for-profit academic purpose) [Word]
          Remarks
          Gateway® Entry clone. Please refer Life Technologies Corporation signs license agreement with RIKEN BRC.
          提供案内 (日本国内) [open/close]

          提供条件 利用者は、研究成果の公表にあたって寄託者の指定する文献を引用する(Uchibori, K et al. Nat. Commun. 8: 14768, 2017)。
          提供依頼 手続きの詳細は、「提供申込みについて[link]」をご覧ください。
          提供依頼書 [Word]
          提供同意書 (MTA、非営利機関による非営利学術研究用)[Word]
          備考
          Gateway®テクノロジーを用いたエントリークローンです。「Gateway®テクノロジーを用いたクローンの提供と寄託のご案内」をご覧ください。

          Catalog # Resource name Shipping form Fee (non-profit org.)
          RDB15494 pENTER-EGFR T790M/L858R DNA solution

          Please review the QC test results indicated by check icon below as well as clone information before placing your order.

          How to cite this biological resource

          Materials & Methods section:

          The pENTER-EGFR T790M/L858R was provided by the RIKEN BRC through the National BioResource Project of the MEXT, Japan (cat. RDB15494).

          Reference section:

          Uchibori, K., Inase, N., Araki, M., Kamada, M., Sato, S., Okuno, Y., Fujita, N., Katayama, R., Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer. Nat. Commun. 8: 14768 (2017). PMID 28287083.

          Further references such as user reports and related articles (go to bottom)


          References and tips

          Featured content


          QC test results

          RIKEN BRC has sequenced portions of this material for quality test.
          Please review the QC test results indicated by check icon as well as clone information before placing your order.

          Test sheet RDB15494_A7K8p1-2.pdf check

          Nucleotide sequence of a portion of this resource (if available).

          Primer: rrnBT1ter_F2 (Pr0531)
          Region: attL1,insert 5'
          Sequence file: RDB15494_A7K8d.seq check
          >D04925A7_A7K8_2_rrnBT1ter_F2_G04_19_ABI24.ab1
              1 NNNNNNNNNN NNNNNNNNCC TTTCGTTTNN TTTGATGCCT GGCAGTTCCN TACTCTCGCG
             61 TTAACGCTAG CATGGNTGTT TTCCCAGTCA CGACGTTGTA AAACGACGGC CAGTCTTAAG
            121 CTCGGGCCCC AAATAATGAT TTTATTTTGA CTGATAGTGA CCTGTTCGTT GCAACAAATT
            181 GATGAGCAAT GCTTTTTTAT AATGCCAACT TTGTACAAAA AAGCAGGCTC CGCGGCCGCC
            241 CCCTTCACCA TGCGACCCTC CGGGACGGCC GGGGCAGCGC TCCTGGCGCT GCTGGCTGCG
            301 CTCTGCCCGG CGAGTCGGGC TCTGGAGGAA AAGAAAGTTT GCCAAGGCAC GAGTAACAAG
            361 CTCACGCAGT TGGGCACTTT TGAAGATCAT TTTCTCAGCC TCCAGAGGAT GTTCAATAAC
            421 TGTGAGGTGG TCCTTGGGAA TTTGGAAATT ACCTATGTGC AGAGGAATTA TGATCTTTCC
            481 TTCTTAAAGA CCATCCAGGA GGTGGCTGGT TATGTCCTCA TTGCCCTCAA CACAGTGGAG
            541 CGAATTCCTT TGGAAAACCT GCAGATCATC AGAGGAAATA TGTACTACGA AAATTCCTAT
            601 GCCTTAGCAG TCTTATCTAA CTATGATGCA AATAAAACCG GACTGAAGGA GCTGCCCATG
            661 AGAAATTTAC AGGAAATCCT GCATGGCGCC GTGCGGTTCA GCAACAACCC TGCCCTGTGC
            721 AATGTGGAGA GCATCCAGTG GCGGGACATA GTCAGCAGTG ACTTTCTCAG CAACATGTCG
            781 ATGGACTTCC AGAACCACCT NNGCAGCTGC CAAAAGTGTG NTCCAAGCTG TCCCNATGNN
            841 ANCTGCTGGG GTGCANGANA NGANAACTGN NAGAAACTNN NCAAAATCAT CTGNGCCCAG
            901 CAGNGCTCCN GGNGCTGCCG NNNNNANNCC NNCCANNGNN NGCNGNCNCA ACCANNGNNC
          961 TNCNNNNNNN NNANGNCCCC CNGGNNANNN NNNNNNN
          //
          Primer: pDONR_R (Pr0071)
          Region: attL2,insert 3'
          Sequence file: RDB15494_A7K8e.seq check
          >D04925A7_A7K8_2_pDONR_R_G05_20_ABI24.ab1
              1 NNNNNNNNNN NNNNCNNTNN NNNTGTAATA CGACTCACTA TAGGGGANAT CAGCTGGATG
             61 GCAAATAATG ATTTTATTTT GACTGATAGT GACCTGTTCG TTGCAACAAA TTGATAAGCA
            121 ATGCTTTCTT ATAATGCCAA CTTTGTACAA GAAAGCTGGG TCGGCGCGCC CACCCTTTCA
            181 TGCTCCAATA AATTCACTGC TTTGTGGCGC GACCCTTAGG TATTCTGCAT TTTCAGCTGT
            241 GGAGCCCTTA AAGATGCCAT TTGGCTTGGC TTCCTTGGGA AAGAAGTCCT GCTGGTAGTC
            301 AGGGTTGTCC AGGCTAATTT GGTGGCTGCC TTTCTGGGCC CAGTGGGCAG GGCTGTCGAA
            361 TGTGCTGTTG ACACAGGTGG GCTGGACAGT GTTGAGATAC TCGGGGTTGC CCACTGCAGT
            421 GCTGTGGGGG TCCTGGTAGT GTGGGTCTCT GCTGGGCGCG GGGTTCAGAG GCTGATTGTG
            481 ATAGACAGGA TTCTGCACAG AGCCAGCGGG CCTTTTGGGA ACGGACTGGT TTATGTATTC
            541 AGGCACTGGG AGGAAGGTGT CGTCTATGCT GTCCTCAGTC AAGGCGCCTG TGGGGTCTGA
            601 GCTGTATCGC TGCAAGAAGC TGTCTTCCTT GATGGGACAG CTTTGCAGCC CATTTCTATC
            661 AATGCAAGCC ACGGTGGAAT TGTTGCTGGT TGCACTCAGA GAGCTCANGA NGGGAGTCCG
            721 TGNCGTGGAG GGGCTGCTGA ANAAGCCCTG CTGTGGGANG ANGTACTCGT CGGCATCCAC
            781 CACGTCGTCC ATGTCTTCTT CATCCNTCAN GGCACGGTAN AANTTGGANT CTGTANGANT
            841 TGNCAAATGC ATTCTTTCNT CCCCCNNNAT GANAAGGTAN CGCNNGGGGN CTCNGGCCAT
            901 TTNNGANAAT TCNATGATCN ACTCNNNGAN NTTTGGGNNN NTATNNNCGN CNNTCNNNNN
          961 NNNNN
          //
          Primer: EGFR-F5 (Pr0313)
          Region: insert mid (T790M/L858R)
          Sequence file: RDB15494_A7K8f.seq check
          >D04925A7_A7K8_2_EGFR-F5_G06_21_ABI24.ab1
              1 NNNNNNNNNN NNNNNNNNNN NNGGNNGGTG GGGGCCCTCC TCTTGCTGCT GGTGGTGGCC
             61 CTGGGGNNCG GCCTCTTCAT GCGAAGGCGC CACATCGTTC GGAAGCGCAC GCTGCGGAGG
            121 CTGCTGCAGG AGAGGGAGCT TGTGGAGCCT CTTACACCCA GTGGAGAAGC TCCCAACCAA
            181 GCTCTCTTGA GGATCTTGAA GGAAACTGAA TTCAAAAAGA TCAAAGTGCT GGGCTCCGGT
            241 GCGTTCGGCA CGGTGTATAA GGGACTCTGG ATCCCAGAAG GTGAGAAAGT TAAAATTCCC
            301 GTCGCTATCA AGGAATTAAG AGAAGCAACA TCTCCGAAAG CCAACAAGGA AATCCTCGAT
            361 GAAGCCTACG TGATGGCCAG CGTGGACAAC CCCCACGTGT GCCGCCTGCT GGGCATCTGC
            421 CTCACCTCCA CCGTGCAGCT CATCATGCAG CTCATGCCCT TCGGCTGCCT CCTGGACTAT
            481 GTCCGGGAAC ACAAAGACAA TATTGGCTCC CAGTACCTGC TCAACTGGTG TGTGCAGATC
            541 GCAAAGGGCA TGAACTACTT GGAGGACCGT CGCTTGGTGC ACCGCGACCT GGCAGCCAGG
            601 AACGTACTGG TGAAAACACC GCAGCATGTC AAGATCACAG ATTTTGGGCG GGCCAAACTG
            661 CTGGGTGCGG AAGAGAAAGA ATACCATGCA GAANGAGGCA AAGTGCCTAT CAAGTGGATG
            721 GCATTGGAAT CAATTTTACA CAGAATCTAT ACCCACCAGA NTGATGTCTG GANCTACNGG
            781 GTGANCGTTT GGGANTTGAN GANCTTNNGA TCCNAGCCAT ATGACGGAAT CCCNGCCAGC
            841 NANNTCTCCT CCNTCCNGGA NAAAGGANAA CGNCTCCNNC ANCCACCCNT ATGNACCNTC
            901 NNNGTCNANN TNATCANGGN NNANNNCTNN NNGANANNNN CANANANNCG NCNNANNNNN
          961 NNNNN
          //

          Please visit Sequencing and PCR primers for primer information.


          References

          Original, user report and related articles

          original Uchibori, K., Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer. Nat. Commun. 8: 14768 (2017). PMID 28287083.

          2023.05.01

          GNP_filter3_RDBDEP_html_230501.pl